• Plasma pharmacokinetics of AG-013736, oxaliplatin, irinotecan and 5-FU, including AUC, Cmax, Cmin, clearance, and t1/2 (Phase 1 portion only) [ Time Frame: Baselines to 36 months ] [ Designated as safety issue: No ]
• Safety profile of treatments based on physical examinations, laboratory tests, and assessment of adverse events [ Time Frame: Baselines to 36 months ] [ Designated as safety issue: No ]
• Tumor response and disease progression according to RECIST. Response rate (including complete and partial responses), duration of response and progression-free survival will be determined in the Phase 2 portion of the study [ Time Frame: Baselines to 36 months ] [ Designated as safety issue: No ]
• Overall Survival [ Time Frame: Until Death ] [ Designated as safety issue: No ]
• Patient-reported outcomes (PROs) of colorectal cancer-specific symptoms [ Time Frame: Baselines to 36 months ] [ Designated as safety issue: No ]

• Determine maximum tolerated doses of bevaxizumab, AG013736, FOLFOX (5FU, Oxaliplatin, leucovorin) given to patients with solid tumors (Ph 1)
• Determine safety of AG013736, FOLFIRI (5FU, irinotecan, leucovorin), with or without bevacizumab (Ph 1)
• Evaluate potential pharmacokinetic (PK) interactions among bevacizumab, AG013736 and FOLFOX (Ph 1)
• Evaluate potential PK interactiosn among bevacizumab, AG013736, and FOLFIRI (Ph 1)
• Evaluate the adverse event profile and dose-limiting toxicities for each combination
• Estimate the response rate, duration of response, progression-free survival, and survival in each arm (Ph 2)
• Evaluate patient-reported outcomes of colorectal cancer-specific symptoms in each arm (Ph 2)

To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.

• Drug: bevacizumab
  bevacizumab 5 mg/kg every 2 weeks
• Drug: AG-013726
  AG-013726 5 mg bid every 2 weeks
• Drug: AG-013736 (axitinib)
  AG-013736 5 mg bid starting dose

• B: Active Comparator
  bevacizumab 5 mg/kg every 2 weeks + FOLFOX
  Intervention: Drug: bevacizumab
• C: Experimental
  AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
  Intervention: Drug: AG-013726
• A: Experimental
  AG-013736 5 mg bid starting dose + FOLFOX
  Intervention: Drug: AG-013736 (axitinib)

Inclusion Criteria:

• (Phase 1) Patients with any solid/GI tumor who have had no more than 1 previous chemotherapy for greater than 3 months prior to enrollment
• (Phase 2) Patients with locally advanced or metastatic colorectal cancer (CRC) previously untreated with any systemic therapy.
• Patients treated with adjuvant chemotherapy (with radiation) will be eligible if last treatment was > 12 months prior to enrollment,
• Patients must have measurable disease by RECIST and if any history of hypertension, it must be controlled with medication.

Exclusion Criteria:

• Prior system therapy for advanced CRC (Ph 2 portion only)
• Prior treatment with anti-angiogenesis agent such as bevacizumab or VEGF inhibitors.
• Prior irradiation of greater than 25% of bone marrow (whole pelvis = 25%)
• Prior radiation, major surgery, or investigational agent within 4 weeks of study entry except palliative radiotherapy to non-target, metastatic lesions. Minor surgeries should be completed > 2 weeks of enrollment and be fully recovered from any procedure.